Higher-Dose Fluvoxamine Fails for COVID Outpatients
The extensive quest to repurpose a cheap therapy for non-hospitalized COVID patients has once again fallen short, this time using a higher dose of fluvoxamine (Luvox), a selective serotonin reuptake inhibitor (SSRI). In the latest readout from the multi-platform ACTIV-6 trial, time to sustained recovery landed at an identical 10 days whether patients with mild […]
Inhaled Glucocorticoid Flops for Speeding COVID Recovery in Outpatients
Inhaled fluticasone furoate failed to shorten recovery time for non-hospitalized adults with COVID-19, new data from the adaptive ACTIV-6 trial found. When used daily for 2 weeks, a quicker COVID-19 recovery time — considered at least 3 consecutive days without symptoms — was no more likely with fluticasone furoate than with placebo (HR 1.01, 95% […]